Carregant...
A Novel RXR Agonist, UAB30, Inhibits Rhabdomyosarcoma Cells in Vitro
BACKGROUND: While patients with early stage rhabdomyosarcoma (RMS) have seen steady improvement in prognosis over the last fifty years, those with advanced stage or high grade disease continue to have a dismal prognosis. Retinoids have been shown to cause growth suppression and terminal differentiat...
Guardat en:
| Publicat a: | J Surg Res |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6007849/ https://ncbi.nlm.nih.gov/pubmed/29907230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jss.2018.02.057 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|